Redeye strengthens its positive view of q.beyond following solid Q3 new sales figures, driven mainly by momentum in the healthcare segment, an early encouraging sign for the recent GITG acquisition. We keep our forecasts for now but expect a positive bias in the upcoming estimate revisions for 2027 and beyond following the full Q3 report.
LÄS MER
